National Marrow Donor Program–Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide

PURPOSE: Hematopoietic cell transplantation (HCT) is curative for hematologic disorders, but outcomes are historically inferior when using HLA-mismatched donors. Despite unrelated donor registries listing > 38 million volunteers, 25%-80% of US patients lack an HLA-matched unrelated donor, with si...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Oncol
Autors principals: Shaw, Bronwen E., Jimenez-Jimenez, Antonio Martin, Burns, Linda J., Logan, Brent R., Khimani, Farhad, Shaffer, Brian C., Shah, Nirav N., Mussetter, Alisha, Tang, Xiao-Ying, McCarty, John M., Alavi, Asif, Farhadfar, Nosha, Jamieson, Katarzyna, Hardy, Nancy M., Choe, Hannah, Ambinder, Richard F., Anasetti, Claudio, Perales, Miguel-Angel, Spellman, Stephen R., Howard, Alan, Komanduri, Krishna V., Luznik, Leo, Norkin, Maxim, Pidala, Joseph A., Ratanatharathorn, Voravit, Confer, Dennis L., Devine, Steven M., Horowitz, Mary M., Bolaños-Meade, Javier
Format: Artigo
Idioma:Inglês
Publicat: Wolters Kluwer Health 2021
Matèries:
ORIGINAL REPORTS
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8260905/
https://ncbi.nlm.nih.gov/pubmed/33905264
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.03502
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars